15 Oct 2025
24m
PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.